JNJ-26366821

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-26366821, covering 2025-04-27 to 2025-04-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants [Phase 1]